Efficacy and toxicity of bevacizumab in recurrent ovarian disease: An update meta-analysis on phase III trials

Claudia Marchetti, Francesca De Felice, Innocenza Palaia, Angela Musella, Violante Di Donato, Maria Luisa Gasparri, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4.
Lingua originaleEnglish
pagine (da-a)13221-13227
Numero di pagine7
RivistaOncotarget
Volume7
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Bevacizumab
  • Ovarian cancer
  • Recurrent
  • Survival
  • Toxicity

Fingerprint

Entra nei temi di ricerca di 'Efficacy and toxicity of bevacizumab in recurrent ovarian disease: An update meta-analysis on phase III trials'. Insieme formano una fingerprint unica.

Cita questo